This selective sensitivity to DMG was seen across AML cells representing distinct genetic drivers (KMT2A, FLT3, NRAS and TP53 mutated), supporting a broader metabolic sensitivity to Glu in AML. This evidence concerns the gene NRAS and acute myeloid leukemia.